news

  • 5 November 2012
    Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award - 1.42m Funding Will Drive Development of New Treatment for Atopic Dermatitis

    Creabilis SA, a European biotechnology company specialising in the development of treatments in dermatology, inflammation and pain today announces that it has been granted a prestigious Biomedical Catalyst funding award, of £1.42m. Creabilis is one of the first companies to receive this award that will be used to advance the development of its clinical stage topical kinase inhibitor, CT327.

    The £180 million Biomedical Catalyst is an integrated translational funding programme jointly operated by the Medical Research Council and the Technology Strategy Board providing responsive and effective support for the best life science opportunities arising in the UK. It was announced by the Prime Minister David Cameron in December 2011 as part of the UK Government’s Life Sciences Strategy.

    The award will be used by Creabilis in a £2.37m project to further develop CT327, a novel, first-in-class topical kinase inhibitor that is in clinical development to treat a number of dermatological diseases. Specifically, the funding will be used to support a Phase IIb clinical study to further evaluate the safety and efficacy of CT327 in patients with Atopic Dermatitis.

    Atopic Dermatitis (AD) is a poorly treated dermatological disorder, often described as an ‘itch with a rash’. The number of people with AD has increased more than three fold in the past 30 years, with over 1 million people affected in the UK alone. It has a significant impact on patients’ and carers’ quality of life, the disease being particularly prevalent amongst children. Although some older treatments exist, there is a significant need for new therapies that are safe for long term use and address all features of the disease, including itch.

    CT327 has been developed using Creabilis’ Low Systemic Exposure (LSE) technology that creates ‘topical-by-design’ drugs optimised for high local and low systemic exposures. Previously, in an international Phase IIa study, CT327 was effective in treating all aspects of AD and has proven safe and well tolerated in a further five clinical studies.

    Dr Eliot Forster, CEO of Creabilis, said: “It is satisfying to have won this highly prestigious award and we are grateful to the Technology Strategy Board for their diligence. We firmly believe that CT327 will make a real difference to patients suffering from Atopic Dermatitis. The Biomedical Catalyst funding will enable us to complete this important study bringing CT327 one step closer to all patients suffering from this common and poorly treated disease.”